Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT1LVF2)

• DTT Name: Cyclin-dependent kinase 9 (CDK9) DTT Info
• Gene Name: CDK9

Molecule-Related Drug & Molecule List

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flavopiridol	DMKSUOI	Acute myeloid leukaemia	2A60	Phase 2	[1]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[2]
AZD4573	DMOYPTK	Haematological malignancy	2B33.Y	Phase 1	[1]
AZD7503	DM8XJD2	Non-alcoholic steatohepatitis	DB92.1	Phase 1	[3]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[4]
CYC065	DM9ODT6	Lymphoma	2A80-2A86	Phase 1	[1]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[5]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
TP-1287	DM3Z07E	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
VIP-152	DMBQ5OL	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[8]

26 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,5-di-substituted pyridine derivative 1	DMEUO8G	N. A.	N. A.	Patented	[9]
4-(thiazol-5-yl)-pyrimidine derivative 1	DM7B81V	N. A.	N. A.	Patented	[9]
4-(thiazol-5-yl)-pyrimidine derivative 2	DMMQFCN	N. A.	N. A.	Patented	[9]
5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	DMHXKFB	N. A.	N. A.	Patented	[9]
Alkyl sulfone derivative 1	DM06U3J	N. A.	N. A.	Patented	[9]
Aminoarylpyridine derivative 1	DMQVZY5	N. A.	N. A.	Patented	[9]
Aryl pyrimidine derivative 1	DM3CVWU	N. A.	N. A.	Patented	[9]
Benzothiazine derivative 1	DMMVHY4	N. A.	N. A.	Patented	[9]
Bipyridine derivative 1	DMPUXL3	N. A.	N. A.	Patented	[9]
Diaryl amine derivative 1	DM06MJH	N. A.	N. A.	Patented	[9]
Flavopiridol analog 1	DMXL3A5	N. A.	N. A.	Patented	[9]
Indole-based analog 13	DMV7DFM	N. A.	N. A.	Patented	[9]
N-(pyridin-2-yl)pyridine methylsulfone derivative 1	DM305UL	N. A.	N. A.	Patented	[9]
N-(pyridin-2-yl)pyrimidin-4-amine derivative 1	DMRE2I3	N. A.	N. A.	Patented	[9]
N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	DMTZ6K9	N. A.	N. A.	Patented	[9]
N-phenyl-pyrimidin-4-amine derivative 1	DMAV8LM	N. A.	N. A.	Patented	[9]
Nitrogen mustard derivative 1	DMXDSYU	N. A.	N. A.	Patented	[9]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[9]
Phenylpyridine derivative 1	DMVHLQM	N. A.	N. A.	Patented	[9]
Phenylpyridine derivative 2	DMTRPE6	N. A.	N. A.	Patented	[9]
PMID26161698-Compound-25	DM4AFHY	N. A.	N. A.	Patented	[9]
PMID26161698-Compound-32	DMRIWKV	N. A.	N. A.	Patented	[9]
Pyrazinylpyridine derivative 1	DMUXQST	N. A.	N. A.	Patented	[9]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	DMOK7CW	N. A.	N. A.	Patented	[9]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[9]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[9]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SCH 727965	DMCJLD1	Acute lymphoblastic leukaemia	2A85	Discontinued in Phase 3	[2]
BAY 10-00394	DMV2DIW	Small-cell lung cancer	2C25.Y	Discontinued in Phase 2	[10]
ZK 304709	DMJ9R4A	Advanced solid tumour	2A00-2F9Z	Discontinued in Phase 1	[2]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NVP-2	DMO5EXL	Solid tumour/cancer	2A00-2F9Z	Preclinical	[11]

14 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	DMJZK40	Discovery agent	N.A.	Investigative	[12]
4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine	DM54MOP	Discovery agent	N.A.	Investigative	[12]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[12]
Deschloroflavopiridol	DMQER8D	Discovery agent	N.A.	Investigative	[13]
MERIOLIN 1	DMJT93H	Discovery agent	N.A.	Investigative	[14]
MERIOLIN 2	DM413XJ	Discovery agent	N.A.	Investigative	[14]
MERIOLIN 3	DMVE95S	Discovery agent	N.A.	Investigative	[14]
MERIOLIN 4	DMIJMZQ	Discovery agent	N.A.	Investigative	[14]
MERIOLIN 5	DMGVLR0	Discovery agent	N.A.	Investigative	[14]
MERIOLIN 6	DMW5AXC	Discovery agent	N.A.	Investigative	[14]
MERIOLIN 7	DM8D3NY	Discovery agent	N.A.	Investigative	[14]
MERIOLIN 8	DM0E95B	Discovery agent	N.A.	Investigative	[14]
PMID19115845C89S	DMB9F2L	Discovery agent	N.A.	Investigative	[15]
PMID20873740C18	DMVHR3Z	Discovery agent	N.A.	Investigative	[16]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [3] ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of BioTheryX.
• [5] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [6] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [7] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [8] VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
• [9] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [10] National Cancer Institute Drug Dictionary (drug id 770319).
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1981).
• [12] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [13] Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
• [14] Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
• [15] First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
• [16] Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.